{"entity":{"id":"hanmi-pharmaceutical","kind":"company","name":"Hanmi Pharmaceutical","aka":["Hanmi Pharm","한미약품","KRX:128940"],"tldr":"Hanmi Pharmaceutical is one of South Korea's largest drug companies, known for its long-acting protein platform and for olmutinib, the third-generation EGFR inhibitor approved in Korea as Olita in 2016.","summary":"Hanmi Pharmaceutical, founded in 1973 and based in Seoul, is a research-driven South Korean pharmaceutical company. Its LAPSCOVERY platform produced efpeglenatide and the neutropenia drug eflapegrastim (Rolvedon), and it has out-licensed several oncology candidates including the pan-RAF inhibitor belvarafenib and the FLT3 inhibitor tuspetinib. Olmutinib (HM61713), a third-generation EGFR T790M inhibitor, received conditional approval in Korea in 2016; Boehringer Ingelheim returned its licence the same year after cases of severe skin toxicity.","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/Hanmi_Pharm","links":[{"label":"Official website","url":"https://www.hanmipharm.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["olmutinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Seoul","country":"KR","companyType":"pharma","website":"https://www.hanmipharm.com/","ticker":"KRX:128940","founded":1973,"stage":"public","investors":[],"funding":[]},"route":"/companies/hanmi-pharmaceutical/","neighbours":{"drug":[{"id":"olmutinib","kind":"drug","name":"Olmutinib","route":"/drugs/olmutinib/"}],"trial":[{"id":"nct07449754","kind":"trial","name":"Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma","route":"/trials/nct07449754/"},{"id":"nct02485652","kind":"trial","name":"Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung","route":"/trials/nct02485652/"},{"id":"nct02444819","kind":"trial","name":"Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy","route":"/trials/nct02444819/"}]}}